Organization (Industry)
PROCTER & GAMBLE Co
ClinicalTrials.gov lists PROCTER & GAMBLE Co as lead sponsor of 83 trials. It has 11 active development programs and 17 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Procter & Gamble. The original uploader was KarimKoueider at English Wikipedia .. Later version(s) were uploaded by Cristianocampo93 , JJMC89 , Ridwan97 at en.wikipedia ., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers PROCTER & GAMBLE Co: 83 lead-sponsored trials and 13 legal-entity registrations.
Disease areas (71)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Gingivitis | 22 |
| Bone Diseases, Metabolic | 19 |
| Osteoporosis | 19 |
| Dentin Sensitivity | 11 |
| Osteoporosis, Postmenopausal | 8 |
Showing 5 of 71 disease areas.
Trials by start year as sponsor or collaborator (28)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 4 |
| 2023 | 3 |
| 2022 | 5 |
| 2021 | 6 |
| 2020 | 4 |
| 2019 | 4 |
| 2018 | 14 |
| 2017 | 4 |
| 2016 | 3 |
Showing 10 of 28 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (11)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| 0.76% Sodium Monofluorophosphate Dentifrice | Gingivitis | Phase 1 | 3 |
| 0.454% Stannous Fluoride Dentifrice | Gingivitis | Phase 1 | 3 |
| 0.454% stannous fluoride | Gingivitis | Not reported | 3 |
| 0.76% sodium monofluorophosphate | Gingivitis | Not reported | 2 |
| 0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM | Gingivitis | Not reported | 2 |
Showing 5 of 11 active programs.
Approved assets (17)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Stannous Fluoride Dentifrice | 7 |
| Sodium monofluorophosphate dentifrice | 2 |
| 0 ppm F | 2 |
| Marketed Toothpaste | 2 |
| 1100 ppm as MFP | 2 |
Showing 5 of 17 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 71% hit target (n=7) | 67% on time (n=9) |
Journals published in (64)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| American heart journal | 6 |
| Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA | 6 |
| The Cochrane database of systematic reviews | 4 |
| The American journal of gastroenterology | 3 |
| The Journal of clinical endocrinology and metabolism | 3 |
Showing 5 of 64 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 17,267 | 2,025 | 2025-12-30 |
SEC-reported annual financials (12)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2026 | 87,032,000,000 | 16,046,000,000 | 2,100,000,000 |
| 2025 | 84,284,000,000 | 15,974,000,000 | 2,100,000,000 |
| 2024 | 84,039,000,000 | 14,879,000,000 | 2,000,000,000 |
| 2023 | 82,006,000,000 | 14,653,000,000 | 2,000,000,000 |
| 2022 | 80,187,000,000 | 14,742,000,000 | 2,000,000,000 |
| 2021 | 76,118,000,000 | 14,306,000,000 | 1,900,000,000 |
| 2020 | 70,950,000,000 | 13,027,000,000 | 1,800,000,000 |
| 2019 | 67,684,000,000 | 3,897,000,000 | 1,900,000,000 |
| 2018 | 66,832,000,000 | 9,750,000,000 | 1,900,000,000 |
| 2017 | 65,058,000,000 | 15,326,000,000 | 1,900,000,000 |
Showing 10 of 12 fiscal years.
Financing and grant events (70)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-11-04 | Debt financing | 258,889,000 | Sec extracted |
| 2025-11-03 | Debt financing | 1,250,000,000 | Sec extracted |
| 2025-10-30 | Debt financing | 258,889,000 | Edgar offerings |
| 2025-10-29 | Debt financing | 1,160,722,401 | Edgar offerings |
| 2025-10-29 | Debt financing | 1,248,525,000 | Edgar offerings |
Showing 5 of 70 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 10 |
FDA recalls (3)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| Vicks NyQuil Cold and Flu Nighttime Relief, Liquid Twin Pack, (Acetaminophen 650mg, Dextromethorphan HBr 30mg, Doxylamine succinate 12.5mg), 12 fl oz (354 ml) bottles, Distributed by Procter & Gamble, Cincinnati, OH 45202, NDC 37000-807-12 | Class II | 2013-08-29 |
| DayQuil Sinex DayTime Sinus Relief (acetaminophen 325 mg and phenylephrine HCl 5 mg) liquicaps and NyQuil Sinex NightTime Sinus Relief (acetaminophen 325 mg, doxylamine succinate 6.25 mg, and phenylephrine HCl 5 mg) liquicaps Combopack, each 48-count liquicaps per carton contains 32 DayQuil Sinex DayTime Liquicaps and 16 NyQuil Sinex NightTime Liquicaps per carton, Made In Canada, Dist. by Procter & Gamble, Cincinnati, OH 45202, UPC 3 23900 01454 1. | Class II | 2013-07-03 |
| Vicks NyQuil Cold & Flu, Nighttime Relief, 12 FL OZ bottle, Dist. by Proctor and Gamble, Cincinnati, OH 45040. NDC 37000-808-12 | Class II | 2012-11-08 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 47 | 2026-05-19 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| PROCTER & GAMBLE CO. | CINCINNATI, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | 2040 |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | 42.0% | not disclosed |
Organization relationships (13)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Vanderbilt University | Co sponsors trial with | 2 |
| University of Chicago | Co sponsors trial with | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
| Autonomous University of Queretaro | Co sponsors trial with | 1 |
| University of Washington | Co sponsors trial with | 1 |
Showing 5 of 13 relationships.
Latest dated events (17,553)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-19 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 17,553 events.
CLIA clinical laboratory certificates (7)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| PROCTER & GAMBLE | Certificate of waiver | Active |
| PROCTER & GAMBLE (WINTON HILL) | Certificate of waiver | Active |
| PROCTER & GAMBLE (F&HC) | Certificate of waiver | Active |
| PROCTER & GAMBLE | Certificate of waiver | Active |
| PROCTER AND GAMBLE | Certificate of waiver | Active |
Showing 5 of 7 certificates.
Biomarker capability evidence (60)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CDA | Trial sponsor | Named in trial inclusion criteria |
| CDA | Trial sponsor | Named in trial inclusion criteria |
| CYP19A1 | Trial collaborator | Named in trial inclusion criteria |
| NF2 | Trial collaborator | Primary endpoint in a Phase 3 trial |
| PAPOLA | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 60 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, and biomarkers this organization publishes on.